Physician profile
Sean M Doyle
NPI 1679694822
$16,665.84
in general payments reported to CMS, 2019-2025
56 companies · $3,050 in 2025
The $3,050 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,962 · 2020: $1,156 · 2021: $1,622 · 2022: $2,032 · 2023: $3,039 · 2024: $1,805 · 2025: $3,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,656 · Travel and Lodging: $1,104 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,655.68 |
| Travel and Lodging | $1,103.63 |
| Education | $134.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,730.47 | 2019-2025 | |
| Janssen Biotech, INC. | $2,114.50 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Dendreon Pharmaceuticals LLC | $2,054.52 | 2019-2025 | Provenge |
| Procept Biorobotics Corporation | $1,791.84 | 2020-2025 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $1,105.11 | 2019-2024 | Xtandi |
| Urogen Pharma, INC. | $847.37 | 2021-2025 | Jelmyto |
| Intuitive Surgical, INC. | $664.30 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $452.05 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $445.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $310.40 | 2022-2025 | |
| Clovis Oncology, INC. | $300.97 | 2020-2022 | |
| Boston Scientific Corporation | $278.13 | 2019-2025 | Lumenis Pulse 120h |
| Tolmar Pharmaceuticals, INC. | $269.00 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $238.24 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Coloplast Corp | $236.47 | 2020-2024 | Speedicath, Porges Coloplast, Isiris Astent Removal Device |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $228.48 | 2023-2025 | Trelstar, Tlando |
| Telix Pharmaceuticals | $208.58 | 2025 | Illuccix |
| Blue Earth Diagnostics | $182.97 | 2019-2025 | Posluma |
| Progenics Pharmaceuticals, INC. | $159.98 | 2021-2024 | Pylarify |
| Sun Pharmaceutical Industries INC. | $154.67 | 2019-2024 | Yonsa |
| Amgen INC. | $137.82 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $132.72 | 2020-2024 | Xiaflex, Aveed |
| Abbvie INC. | $121.03 | 2019-2024 | Botox |
| Smith+Nephew, INC. | $118.61 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $114.86 | 2020-2025 | Lynparza, Imfinzi |
| Urovant Sciences INC | $113.40 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $94.63 | 2023-2025 | Prolaris |
| Profound Medical Corp. | $79.71 | 2022 | |
| Accord Healthcare, INC. | $76.06 | 2023 | |
| Olympus America INC. | $71.11 | 2025 | Itind System |
| Teleflex LLC | $70.94 | 2022-2025 | Urolift, Barrigel |
| Therapeuticsmd, INC. | $66.07 | 2019-2020 | |
| Myovant Sciences INC. | $62.78 | 2021-2022 | |
| Travere Therapeutics, INC. | $58.93 | 2019-2020 | |
| Immunitybio, INC. | $55.08 | 2024-2025 | |
| Novo Nordisk INC | $46.99 | 2024-2025 | Rivfloza |
| Alnylam Pharmaceuticals INC. | $42.81 | 2023 | Givlaari |
| Tolmar, INC. | $42.28 | 2023 | |
| Antares Pharma, INC. | $41.66 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Endo USA, INC. | $36.32 | 2025 | Xiaflex |
| Hollister Incorporated | $32.33 | 2021 | |
| Clarus Therapeutics INC. | $31.40 | 2021 | |
| Zyla Life Sciences, INC. | $27.93 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $27.14 | 2025 | |
| Ferring Pharmaceuticals INC. | $22.25 | 2025 | Adstiladrin |
| Mission Pharmacal Company | $20.96 | 2021 | |
| Medtronic USA, INC. | $20.17 | 2019 | |
| Photocure INC | $20.05 | 2022 | |
| Allergan, INC. | $18.83 | 2020 | |
| Urogpo LLC | $16.98 | 2019 | |
| Palette Life Sciences, INC. | $16.32 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.61 | 2023 | Opdivo |
| Civco Medical Instruments | $14.36 | 2025 | |
| Eisai INC. | $12.87 | 2021 | |
| Baudax Bio INC. | $12.01 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.